| Autor: |
Aguiar Santiago JA; Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Marrero Miragaya MA; Clinical Trial National Coordinator (CENCEC), Havana, Cuba., Figueroa Oliva DA; Clinical Trial National Coordinator (CENCEC), Havana, Cuba., Aguilar Juanes A; Clinical Trial National Coordinator (CENCEC), Havana, Cuba., Idavoy Corona A; Clinical Trial National Coordinator (CENCEC), Havana, Cuba., Martínez Fernández S; Clinical Trial National Coordinator (CENCEC), Havana, Cuba., Morán Bertot I; Plant Molecular Biology Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Rodríguez Hernández M; Plant Genomic Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Canales López E; Plant Genomic Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Hernández Esteves I; Plant Genomic Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Silva Girado JA; Olinonucleotide Synthesis Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Estrada Vázquez RC; Olinonucleotide Synthesis Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Gell Cuesta O; Olinonucleotide Synthesis Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Mendoza-Marí Y; Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Valdés Prado I; Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Rodríguez Ibarra C; Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Palenzuela Gardon DO; Mammalian Genomic Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Pentón Arias E; Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Guillén Nieto G; Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Aguilar Rubido JC; Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. |
| Abstrakt: |
HeberNasvac, a therapeutic vaccine for chronic hepatitis B, is able to safely stimulate multiple Toll-like receptors, increasing antigen presentation in vitro and in a phase II clinical trial (Profira) in elderly volunteers who were household contacts of respiratory infection patients. Thus, a new indication as a postexposure prophylaxis or early therapy for respiratory infections has been proposed. In this study, we evaluated the expression of several interferon-stimulated genes (ISGs) after mucosal administration of HeberNasvac and compared this effect with the nasal delivery of interferon alpha 2b (Nasalferon). Molecular studies of blood samples of 50 subjects from the Profira clinical trial who were locally treated with HeberNasvac or Nasalferon and concurrent untreated individuals were compared based on their relative mRNA expression of OAS1, ISG15, ISG20, STAT1, STAT3, and DRB1-HLA II genes. In most cases, the gene expression induced by HeberNasvac was similar in profile and intensity to the expression induced by Nasalferon and significantly superior to that observed in untreated controls. The immune stimulatory effect of HeberNasvac on ISGs paved the way for its future use as an innate immunity stimulator in elderly persons and immunocompromised subjects or as part of Mambisa, a nasal vaccine to prevent severe acute respiratory syndrome coronavirus 2 infection. |
